Svetlana Loshakov, CFA

Svetlana Loshakov, CFA

Servier Voluntary Public Offer for all Outstanding Shares of Egis Pharmaceuticals PLC - Yahoo Financ...

Tue, Sep 24, 2013, 4:23 AM EDT - U.S. Markets open in 5 hrs 7 mins Pascal Touchon, Head of Business Development and Scientific Cooperation, announced Servier Group's voluntary public offer for all outstanding shares of a majority-owned company, Egis, at a price of 28,000 HUF per share. ...

Pascal Touchon

Mentioned in this article:
Pascal Touchon

Curie Cancer And Servier Continue A Renewed

Servier - The company allocates over 25 per cent of its turnover to this activity, making it one of the leading international pharmaceutical laboratories,” said Pascal Touchon, Servier's director of scientific collaboration. “Servier is delighted with the Institut Curie partnership, which fulfills ...

Pascal Touchon

Mentioned in this article:
Pascal Touchon

Servier Voluntary Public Offer for all Outstanding Shares of Egis Pharmaceuticals PLC -- LONDON, Se...

Pascal Touchon, Head of Business Development and Scientific Cooperation, announced Servier Group's voluntary public offer for all outstanding shares of a majority-owned company, Egis, at a price of 28,000 HUF per share. Touchon added that Egis is their only affiliate to be listed on a ...

Cellectis Servier Forge Leukemia Solid Tumors Pact

Servier - Combining Cellectis’ technical expertise with Servier’s scientific, medical and financial resources will create an exciting new alliance to fuel the development of our unique, novel allogeneic cancer therapies, ultimately benefitting many patients around the world.” Jean-Pierre Abastado...

Jean-Pierre Abastado

Mentioned in this article:
Jean-Pierre Abastado

Servier stages an entry into high-stakes CAR-T showdown with Novartis - FierceBiotech

Servier - Jean-Pierre Abastado, who heads up the Oncology Innovation Center at Servier, noted that "these original cell-based therapies will well complement Servier's innovative clinical oncology pipeline, which currently includes immunotherapeutic monoclonal antibodies, an HDAC inhibitor, kinase ...

Jean-Pierre Abastado

Mentioned in this article:
Jean-Pierre Abastado

Servier offers $483M to buy out other Egis shareholders - FiercePharma

Servier - In a Q&A posted on the French drugmaker's website, business development chief Pascal Touchon said his company won't increase the price. "We are not planning any post-bids after the acceptance period regardless of the original bid's outcome," Touchon stated. Egis is a generics company ...

Join Newsle to find out when Svetlana Loshakov, CFA makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Svetlana Loshakov, CFA
  • See news articles & blog posts about Svetlana Loshakov, CFA
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL